Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients suspected of having invasive breast cancer, \>1 cm in diameter, and in whom there is an indication for a core or incision biopsy~* Age \<75 years at time of diagnosis~* Patient willing and able to comply with the study prescriptions~* Patient able to give written informed consent before patient registration/randomisation~* Pre- and post-menopausal patients are eligible~* Hormone receptor positive and negative patients are eligible~* A negative pregnancy test in pre-menopausal women~Exclusion Criteria:~* HIV, HBV or HCV positivity~* Known hypersensitivity to NSAIDs~* A history of upper gastro-intestinal bleeding~* Endoscopically proven upper gastro-intestinal ulceration~* Patients using NSAIDs, including salicyclic acid~* Systemic use of corticosteroids~* A history or the presence of any other malignancy excepting adequately treated squamous cell skin cancer or in situ carcinoma of the cervix~* Patients who have been treated with neo-adjuvant chemotherapy or hormone therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): pre-operative placebo twice daily for two to three weeks
- celecoxib (Type: EXPERIMENTAL): pre-operative celecoxib (400 mg) twice daily for two to three weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).